These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33004158)

  • 1. A comprehensive review of partial opioid agonists for the treatment of chronic pain.
    Gress K; Charipova K; Jung JW; Kaye AD; Paladini A; Varrassi G; Viswanath O; Urits I
    Best Pract Res Clin Anaesthesiol; 2020 Sep; 34(3):449-461. PubMed ID: 33004158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Full µ-Opioid Receptor Agonists is not Impaired by Concomitant Buprenorphine or Mixed Opioid Agonists/Antagonists - Preclinical and Clinical Evidence.
    van Niel JC; Schneider J; Tzschentke TM
    Drug Res (Stuttg); 2016 Nov; 66(11):562-570. PubMed ID: 27504867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid agonist-antagonist drugs in acute and chronic pain states.
    Hoskin PJ; Hanks GW
    Drugs; 1991 Mar; 41(3):326-44. PubMed ID: 1711441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel G Protein-Biased Agonist at the
    Conibear AE; Asghar J; Hill R; Henderson G; Borbely E; Tekus V; Helyes Z; Palandri J; Bailey C; Starke I; von Mentzer B; Kendall D; Kelly E
    J Pharmacol Exp Ther; 2020 Feb; 372(2):224-236. PubMed ID: 31594792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence.
    Bidlack JM
    Adv Pharmacol; 2014; 69():387-418. PubMed ID: 24484983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous Perioperative Sublingual Buprenorphine.
    Silva MJ; Rubinstein A
    J Pain Palliat Care Pharmacother; 2016 Dec; 30(4):289-293. PubMed ID: 27736284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.
    Davis MP; Pasternak G; Behm B
    Drugs; 2018 Aug; 78(12):1211-1228. PubMed ID: 30051169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biased versus Partial Agonism in the Search for Safer Opioid Analgesics.
    Azevedo Neto J; Costanzini A; De Giorgio R; Lambert DG; Ruzza C; Calò G
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32854452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioids for chronic non-cancer pain in children and adolescents.
    Cooper TE; Fisher E; Gray AL; Krane E; Sethna N; van Tilburg MA; Zernikow B; Wiffen PJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012538. PubMed ID: 28745394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment.
    Withey SL; Spealman RD; Bergman J; Paronis CA
    J Pharmacol Exp Ther; 2019 Nov; 371(2):544-554. PubMed ID: 31413139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Utilization of Mu-Opioid Receptor Biased Agonists: Oliceridine, an Opioid Analgesic with Reduced Adverse Effects.
    Urits I; Viswanath O; Orhurhu V; Gress K; Charipova K; Kaye AD; Ngo A
    Curr Pain Headache Rep; 2019 Mar; 23(5):31. PubMed ID: 30880365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of cell culture assays and knockout mouse analyses for the study of opioid partial agonism.
    Ide S; Minami M; Sora I; Ikeda K
    Methods Mol Biol; 2010; 617():363-74. PubMed ID: 20336435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction.
    Robinson SE
    CNS Drug Rev; 2002; 8(4):377-90. PubMed ID: 12481193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics.
    Pedersen MF; Wróbel TM; Märcher-Rørsted E; Pedersen DS; Møller TC; Gabriele F; Pedersen H; Matosiuk D; Foster SR; Bouvier M; Bräuner-Osborne H
    Neuropharmacology; 2020 Apr; 166():107718. PubMed ID: 31351108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion.
    Webster L; Gudin J; Raffa RB; Kuchera J; Rauck R; Fudin J; Adler J; Mallick-Searle T
    Pain Med; 2020 Apr; 21(4):714-723. PubMed ID: 31917418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists.
    Picker MJ; Benyas S; Horwitz JA; Thompson K; Mathewson C; Smith MA
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1130-41. PubMed ID: 8968334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Systems Pharmacology and Biased Agonism at Opioid Receptors: A Potential Avenue for Improved Analgesics.
    Bedini A; Cuna E; Baiula M; Spampinato S
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists.
    Picker MJ; Dykstra LA
    J Pharmacol Exp Ther; 1989 May; 249(2):557-66. PubMed ID: 2566680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The mu, delta and kappa properties of various opioids].
    Ohta S; Niwa M; Nozaki M; Hattori M; Shimonaka H; Dohi S
    Masui; 1995 Sep; 44(9):1228-32. PubMed ID: 8523655
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.